Abstracts tagged "autoimmune diseases"

Abstract Number: 1999 • ACR Convergence 2024
Effects of JAK Inhibitors on Subsets of the Innate Immune System
Carmen Lasa Teja¹, Juan José Fernández-Cabero², Alejandra Comins-Boo³, David San Segundo³, Marcos Lopez-Hoyos⁴ and Ricardo Blanco-Alonso⁵, ¹Hospital Universitario Marqués de Valdecilla, Riotuerto, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease caused by genetic and environmental factors characterised by joint inflammation. The JAK-STAT inhibitors (jakinibs) are among…
Abstract Number: 2253 • ACR Convergence 2024
A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB002, an Anti-TNFα mAb Designed for Extended Half-life, in Healthy Volunteers
Cory Sellwood¹, Minggeng Gao², Mark Matijevic², Stephen Wax³, Mason Yamashita², Shan Yu², Sujata Arora² and Rachel Kirk², ¹New Zealand Clinical Research, Christchurch, New Zealand, ²Zenas BioPharma, Waltham, MA, ³Former Employee of Zenas Biopharma, Newton, MA
Background/Purpose: ZB002 is a recombinant human monoclonal antibody (mAb) that targets human TNFα with an Fv domain identical in amino acid sequence to adalimumab and…
Abstract Number: 2436 • ACR Convergence 2024
Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus
Florian Kollert¹, Sarah Robertson², Veit Erpenbeck², Franziska Regenass-Lechner³, Remy Hallet³, Jason Neale², Cary M. Looney², Nicolas Frances², Celine Marban-Doran², Sophia Fredrika Soehrman Brossard², Laurie Millar⁴, Beki Finch⁵, Johannes Sam⁶, Benjamin A. Fisher⁷, Maria Leandro⁸, Thomas Dörner⁹, Christian Klein¹⁰ and Franz Schuler², ¹University Hospital Basel, Basel, Switzerland, ²F. Hoffmann-La Roche Ltd., Basel, Switzerland, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴F. Hoffmann-La Roche Ltd., Welwyn Garden City, England, United Kingdom, ⁵F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom, ⁶F. Hoffmann-La Roche Ltd, Schlieren, Zurich, Switzerland, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University College London, London, United Kingdom, ⁹Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ¹⁰F. Hoffman-La Roche Ltd., Schlieren, Zurich, Switzerland
Background/Purpose: CD20-directed B-cell depletion therapy shows efficacy in hematological malignancies and in multiple autoimmune indications. More recently, promising data for the use of CD19-targeted B-cell…
Abstract Number: 2597 • ACR Convergence 2024
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Jia (Sijia) Chen¹, Roopa Madhu², Catherine Manning³, Daniel Montoro⁴, Nataliya Yeremenko⁵, Kevin Wei⁶, ilya Korsunsky¹, Dominique Baeten⁵ and Ellen Gravallese⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital, Dedham, MA, ⁴TenSixty Biosciences, Boston, MA, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
Abstract Number: PP15 • ACR Convergence 2024
Breathing Mindfully and How to Control Anxiety in Lupus Patients
Amanda Greene, Lupus Research Alliance, Los Angeles, CA
Background/Purpose: For over four decades, Systemic Lupus Erythematosus has impacted my Quality of Life.. I was diagnosed in 1983- my entire life was changed. I…
Abstract Number: 0015 • ACR Convergence 2024
Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution
Ana Merino Vico¹, Yosta Vegting¹, Aldo Jongejan¹, Jan Piet van Hamburg¹, Perry moerland¹, Sander Tas² and Marc Hilhorst¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
Abstract Number: 0146 • ACR Convergence 2024
Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions
Bashar Tanous¹, SRIKAR SAMA², Nidaa Rasheed³ and Candice Reyes⁴, ¹UCSF Fresno, Fresno, ²University of California San Francisco Fresno, Fresno, CA, ³UCSF Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
Abstract Number: 0293 • ACR Convergence 2024
Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Autoimmune diseases are known to be associated with an increased risk of many types of cancers. This study investigates the association between different types…
Abstract Number: 0379 • ACR Convergence 2024
Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children
Athimalaipet Ramanan¹, Catherine Guly², Gabriele Simonini³, Stuart Keller⁴, Priyanka Sen⁴, Thorsten Holzkaemper⁴ and PIERRE QUARTIER⁵, ¹Bristol Royal Hosp for Children, Bristol, United Kingdom, ²University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, ³Meyer Children’s Hospital IRCCS; University of Florence, Florence, Toscana, Italy, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France
Background/Purpose: Baricitinib could target multiple cytokine pathways associated with juvenile idiopathic arthritis associated uveitis (JIA-U) and antinuclear antibody (ANA)-positive uveitis, providing a novel therapeutic approach.…
Abstract Number: 0607 • ACR Convergence 2024
Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Andrea Fava¹, Michelle Petri², David Jayne³, Patrick G Gavin⁴, Eszter Csomor⁵, Philip Z Brohawn⁴, Daniel Muthas⁶, Adam Platt⁵, Catharina Lindholm⁷ and Nicola Ferrari⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of Cambridge, Cambridge, United Kingdom, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
Abstract Number: 0780 • ACR Convergence 2024
Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy
Carlo Tur¹, Markus Eckstein², Velden Joachim³, Christina Bergmann⁴, Janina Auth¹, Laura Bucci¹, Giulia Corte⁵, Melanie Hagen¹, Andreas Wirsching¹, Ricardo Grieshaber-Bouyer¹, Petra Reis¹, Nicolai Kittan¹, Jochen Wacker¹, Simon Rauber¹, Aleix Rigau⁶, Andreas Ramming¹, Maria Antonietta D'Agostino⁷, Arndt Hartmann⁸, Fabian Müller⁹, Andreas MAckensen¹⁰, Aline Bozec¹, Georg Schett¹¹ and Maria Gabriella Raimondo¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ⁶Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁸Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹⁰Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has proved potential for achieving long-term drug-free remission in patients with autoimmune diseases (AIDs). Its effectiveness likely…
Abstract Number: 0889 • ACR Convergence 2024
Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics
Tomás Gomes¹, Matilde Bandeira², Rui do Amaral Vieira¹, Bianca Correia¹, Sofia Barreira³, Pedro Gaspar⁴, Rita Cruz-Machado⁵, Beatriz Filipe¹, Pedro Ávila-Ribeiro¹, Filipa Ribeiro¹, Bruno Vidal¹, Beatriz Val¹, Filipa Costa⁶, Ana Teodósio Chícharo⁷, Augusto Silva¹, Manuel Silvério-Antonio¹, João Forjaz Lacerda¹, João Eurico Fonseca¹, Dolores López Presa⁸, Nikita Khmelinskii¹, Saumya Kumar⁹, Luis Graca¹ and Vasco C. Romão¹⁰, ¹Instituto de Medicina Molecular (iMM Lisboa), Lisboa, Portugal, ²Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ³Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisbon, Portugal, ⁴Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, ⁵Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisboa, Portugal, ⁶Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, ⁷Unidade Local de Saúde do Algarve, Hospital de Faro, Faro, Portugal, Faro, Portugal, ⁸Pathology Department, Unidade Local de Saúde de Santa Maria, Lisbon Academic Medical Centre, Lisboa, Portugal, ⁹TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany, Hannover, Germany, ¹⁰Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands, causing tissue deterioration and loss of function. Disease progression…
Abstract Number: 0967 • ACR Convergence 2024
Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions
Hadijat Makinde¹, Miranda Gurra¹, Salina Dominguez², Matthew Dapas², Tyler Therron², Kathleen Aren³, Marie-Pier Tetreault², Monique Hinchcliff⁴, Deborah Winter⁵ and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University Division of Rheumatology, Chicago, IL, ⁴Yale School of Medicine, Westport, CT, ⁵Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with gastroesophageal reflux, leading to…
Abstract Number: 1121 • ACR Convergence 2024
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases
Alan Kivitz¹, Stanley Cohen², Annie Lau-Kilby³, Yajing Sun³, Jiayin Huang³, Atasi Jana³, Susie Kim³, Yanping Wu³, Quinnie Yang³ and Lin Zhao³, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Metroplex Clinical Research Center, dallas, TX, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: AMG 329 (formerly HZN-1116), a human monoclonal antibody (mAb), binds to soluble and membrane-bound human feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand…
Abstract Number: 1406 • ACR Convergence 2024
Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease
Negaar Goudarzi¹, Loïc Meudec², Juliette Pascaud², Fanny Jaulin³, Quentin Pascal⁴, Thierry Lazure⁵, Sacha E Silva Saffar², Xavier Mariette⁶ and Gaetane Nocturne⁶, ¹University Paris-Saclay, Le Kremlin Bicêtre, France, ²University Paris Saclay, Le Kremlin Bicetre, France, ³Institut Gustave Roussy, Villejuif, France, ⁴CEA, Fontenay aux roses, France, ⁵APHP. Université Paris-Saclay, Hôpital Bicêtre, Anatomie et cytologie pathologiques, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease that manifests as glandular dryness and systemic symptoms. Salivary gland epithelial cells (SGEC) are pivotal in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].